Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones
On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial...
United States Hans Vitzthum Sandesh Seth Actinium Technology Platform Lifesci Advisors Alpha Therapy Program
Source: prnewswire.com